Clinical Outcomes of Next-Generation Microwave Thermosphere Ablation for Hepatocellular Carcinoma with Primarily Hepatitis-Related Etiology
Preprint
- 26 October 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background and aim We investigated the clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent next-generation microwave thermosphere ablation (MTA). Methods A total of 429 patients with 607 HCCs (maximum tumor diameter ≤40 mm) were included. Results The primary etiologies of HCC were hepatitis-related: 259 (60.4%) cases of HCV, 31 (7.3%) cases of HBV, and two instances of both. Median maximum tumor diameter was 15.0 (interquartile range, 10.0–21.0) mm. There were 86 tumors in areas of the liver where MTA is difficult. The most common area was near the primary and secondary branches of the intrahepatic portal vein (26 nodules). The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.4%, 8.0%, and 8.5%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: ≤20 mm group (n=483), 20–30 mm group (n=107), and ≥30 mm group (n=17) (p<0.001). The cumulative local tumor recurrence rate was similar by difficult-to-treat status (p=0.169). In the multivariable analysis, tumor size (per 1 mm) (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.03–1.11; p<0.001) and ablative margin (per 1 mm) (HR, 0.81; 95% CI, 0.70–0.92; p=0.002) were significantly associated with local tumor recurrence. Only tumor size (per 1 mm) (odds ratio, 1.08; 95% CI, 1.02–1.15; p=0.015) was significantly associated with complications. Conclusions MTA is a safe and effective local ablation therapy for HCC, even for tumors located in areas of the liver where local ablation therapy is difficult.Keywords
All Related Versions
- Version 1, 2023-10-26, Preprints
- Published version: Journal of Clinical Medicine, 12 (24), 7577.
This publication has 18 references indexed in Scilit:
- Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus ConferenceHepatology, 2020
- Ex vivo validation of microwave thermal ablation simulation using different flow coefficients in the porcine liverMedical Engineering & Physics, 2019
- Temperature monitoring during microwave ablation in ex vivo porcine liversEuropean Journal of Surgical Oncology, 2015
- The Emprint™ Ablation System with Thermosphere™ Technology: One of the Newer Next-Generation Microwave Ablation TechnologiesSeminars in Interventional Radiology, 2015
- Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: A long-term cohort studyHepatology, 2010
- Microwave Tumor Ablation: Mechanism of Action, Clinical Results, and DevicesJournal of Vascular and Interventional Radiology, 2010
- Novel advancements in the management of hepatocellular carcinoma in 2008Journal of Hepatology, 2008
- A Randomized Controlled Trial of Radiofrequency Ablation With Ethanol Injection for Small Hepatocellular CarcinomaGastroenterology, 2005
- Local ablation therapy for hepatocellular carcinoma: current status and future perspectivesJournal of Gastroenterology, 2004
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999